Sequential treatment of daylight photodynamic therapy and imiquimod 5% cream for the treatment of superficial basal cell carcinoma on sun exposed areas

Paolino, Giovanni; Didona, Dario; Scarnò, Marco; Tallarico, Mariagrazia; Cantoresi, Franca; Calvieri, Stefano; Mercuri, Santo Raffaele; Piccolo, Domenico; Bottoni, Ugo; Kyriakou, Aikaterini; Cantisani, Carmen

doi:10.1111/dth.12788

Cited by 6 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is limited experience of DL MAL‐PDT for sBCC, which cleared 90% of 30 lesions at 3 months, although six recurrences occurred during 12 months of follow‐up . Sequential topical imiquimod 5% cream followed by DL MAL‐PDT vs. PDT alone in sBCC achieved improved response rate if patient had two or more BCC, although no difference was observed for patients with single lesions …”

Section: Basal Cell Carcinomamentioning

confidence: 99%

“…35 Sequential topical imiquimod 5% cream followed by DL MAL-PDT vs. PDT alone in sBCC achieved improved response rate if patient had two or more BCC, although no difference was observed for patients with single lesions. 129 Nanoemulsion ALA-PDT was compared with MAL in the treatment of non-aggressive BCC in a randomized, phase III trial with 281 patients randomized. Of the ALA-treated patients, 93.4% were complete responders compared with 91.8% in the MAL group, establishing non-inferiority, with recurrence rate <10% by 1 year.…”

Section: Basal Cell Carcinomamentioning

confidence: 99%

See 1 more Smart Citation

European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 1: treatment delivery and established indications – actinic keratoses, Bowen's disease and basal cell carcinomas

Morton¹,

Szeimies

Basset-Séguin

et al. 2019

Acad Dermatol Venereol

138

146

View full text Add to dashboard Cite

Topical photodynamic therapy (PDT) is a widely approved therapy for actinic keratoses, Bowen's disease (squamous cell carcinoma in situ), superficial and certain thin basal cell carcinomas. Recurrence rates when standard treatment protocols are used are typically equivalent to existing therapies, although inferior to surgery for nodular basal cell carcinoma. PDT can be used both as lesional and field therapies and has the potential to delay/reduce the development of new lesions. A protocol using daylight to treat actinic keratoses is widely practised, with conventional PDT using a red light after typically a 3‐h period of occlusion employed for other superficial skin cancer indications as well as for actinic keratoses when daylight therapy is not feasible. PDT is a well‐tolerated therapy although discomfort associated with conventional protocol may require pain‐reduction measures. PDT using daylight is associated with no or minimal pain and preferred by patient. There is an emerging literature on enhancing conventional PDT protocols or combined PDT with another treatment to increase response rates. This guideline, published over two parts, considers all current approved and emerging indications for the use of topical PDT in dermatology, prepared by the PDT subgroup of the European Dermatology Forum guidelines committee. It presents consensual expert recommendations reflecting current published evidence.

show abstract

Section: Basal Cell Carcinomamentioning

confidence: 99%

Section: Basal Cell Carcinomamentioning

confidence: 99%

European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 1: treatment delivery and established indications – actinic keratoses, Bowen's disease and basal cell carcinomas

Morton¹,

Szeimies

Basset-Séguin

et al. 2019

Acad Dermatol Venereol

138

146

View full text Add to dashboard Cite

show abstract

“…Topical 5-fluorouracil (5-FU) 5% cream, and imiquimod 5% cream are approved for the treatment of superficial BCC [ 192 , 193 , 194 , 195 , 196 ]. In an RCT that used twice daily imiquimod 5% for 12 weeks, Geisse et al reported a 100% histologic clearance after 6 weeks of treatment [ 193 ].…”

Section: Treatment Of Localized Bccmentioning

confidence: 99%

Basal Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches

et al. 2020

Self Cite

View full text Add to dashboard Cite

Basal cell carcinoma (BCC) is the most common human cancer worldwide, and is a subtype of nonmelanoma skin cancer, characterized by a constantly increasing incidence due to an aging population and widespread sun exposure. Although the mortality from BCC is negligible, this tumor can be associated with significant morbidity and cost. This review presents a literature overview of BCC from pathophysiology to novel therapeutic approaches. Several histopathological BCC subtypes with different prognostic values have been described. Dermoscopy and, more recently, reflectance confocal microscopy have largely improved BCC diagnosis. Although surgery is the first-line treatment for localized BCC, other nonsurgical local treatment options are available. BCC pathogenesis depends on the interaction between environmental and genetic characteristics of the patient. Specifically, an aberrant activation of Hedgehog signaling pathway is implicated in its pathogenesis. Notably, Hedgehog signaling inhibitors, such as vismodegib and sonidegib, are successfully used as targeted treatment for advanced or metastatic BCC. Furthermore, the implementation of prevention measures has demonstrated to be useful in the patient management.

show abstract

“…However, they suggest a possible application in sBCC, as yet no published studies in this regard. The combination of topical treatments, such as PDT and imiquimod 5% cream, have been published 10 …”

Section: Discussionmentioning

confidence: 99%

Treatment of superficial basal cell carcinoma with 7.8% 5‐aminolaevulinic acid nanoemulsion‐based gel ( BF ‐200 ALA ) and photodynamic therapy: Results in clinical practice in a tertiary hospital

Navarro‐Triviño

Ayén‐Rodríguez

Llamas‐Molina

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is an effective treatment option for the treatment of superficial basal cell carcinoma (sBCC). Recent publications have demonstrated that PDT with 7.8% 5‐aminolaevulinic acid nanoemulsion‐based gel (BF‐200 ALA‐PDT) is an effective and safe alternative for the treatment of sBCC). To investigate the efficacy and safety of 7.8% 5‐aminolaevulinic acid nanoemulsion‐based gel (BF‐200 ALA)‐PDT for the treatment of sBCC. A non‐controlled, open‐label single centre study was conducted. Patients received one PDT cycle with two PDT sessions one‐week apart. In case that clinical‐dermoscopy evaluation of treatment outcome revealed remaining lesions, a second PDT cycle was performed. The clinical results at the dermoscopy and fluorescence diagnosis level were histologically confirmed in all patients. Treatment response was evaluated 3, 6, and 12 months after last PDT session. A total of 31 patients (12 men and 19 women), with a median age of 63.74 years were included in this study. 3‐month after PDT‐session, 23/31 patients were complete responders (74.19%) after two BF‐200 ALA ‐PDT sessions. Esthetic outcome was considered good‐to‐excellent. 5 Aminolevulinic acid 7.8% nanoemulsion‐based gel (BF‐200 ALA) PDT is an effective therapy option for the treatment of sBCC. Complete clearance rates were higher in those patients who received only one PDT cycle. These results show a similar tendency as shown in other publications.

show abstract

Sequential treatment of daylight photodynamic therapy and imiquimod 5% cream for the treatment of superficial basal cell carcinoma on sun exposed areas

Cited by 6 publications

References 6 publications

European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 1: treatment delivery and established indications – actinic keratoses, Bowen's disease and basal cell carcinomas

European Dermatology Forum guidelines on topical photodynamic therapy 2019 Part 1: treatment delivery and established indications – actinic keratoses, Bowen's disease and basal cell carcinomas

Basal Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches

Treatment of superficial basal cell carcinoma with 7.8% 5‐aminolaevulinic acid nanoemulsion‐based gel ( BF ‐200 ALA ) and photodynamic therapy: Results in clinical practice in a tertiary hospital

Contact Info

Product

Resources

About